Home > People > Our Team > Arthur Brothag

Arthur Brothag

Partner

Bio

Arthur Brothag is a Partner in the Healthcare team and joined Apax Partners in 2009. He is based in the London office. Arthur has participated in a number of key deals, including Rodenstock, Acelity (formerly known as KCI), EVRY, Neuraxpharm, Unilabs and Vyaire Medical. 

Prior to joining Apax, Arthur worked in the healthcare teams at the private equity firm Warburg Pincus, as well as Morgan Stanley, both in London.

Arthur trained as a medical doctor with a state diploma and a doctorate from the Technical University of Munich; he held resident positions at University hospitals in Germany and Switzerland in internal medicine (cardiology and oncology). In addition to his medical and research training, he also completed his MBA studies with distinction at INSEAD Business School.

Boards

Arthur holds/has held Board memberships of Rodenstock, Acelity (KCI), Neuraxpharm, Unilabs and Vyaire Medical.

Living our values

"“Diagnose, analyse, plan and act” was the mantra that was drilled into me during my medical training at some of the best hospitals in the world. I apply this at Apax: “diagnosing” attractive investment opportunities, “analysing” investment risk and return to optimise each deal and bring it to fruition, “planning” value creation strategies by collaborating with management teams, and then “acting” to deliver them. The value of having “impact through insight and tenacity” is therefore one I have always identified with."

Contact information

+44 20 7872 6300

Office

London

Sector

Healthcare

Arthur's Story

Arthur finds healthcare a deeply fulfilling area to invest in. His experience working as a medical doctor enables him to really visualise the impact that the Apax Funds’ investments in innovative healthcare products and services can deliver for the actual individual – an individual who is not merely a customer, but someone’s mother, father, grandparent or child. Arthur believes that happy patients lead to happy clinicians – and excellent economic returns.